Core Brand Group Strategy - The core brand group of Volkswagen plans to reduce management positions and consolidate its platform to achieve cost savings of 1 billion euros ($1.2 billion) [1]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers   2025 medtech sales: $33.79 billion 6.1% growth year over year   Cardiovascular sales: $8.93 billion 15.8% growth year over year   Orthopedic sales: $9.26 billion 1.1% growth year over year Johnson & Johnson’s cardiovascular segment fueled strong sales growth for the healthcare giant’s medical device business in 2025. The cardiovascular bus ...

Kenvue Inc. (NYSE:KVUE) is included on our list of the best undervalued wide moat stocks. ISS Backs Kenvue (KVUE) Deal, Investors Debate Tylenol and Litigation Risks Kenvue Inc. (NYSE:KVUE) is looking to potentially reshape the consumer health landscape, as it received institutional support for its proposed merger with Kimberly-Clark. On January 16, 2026, Reuters reported that Institutional Shareholder Services (ISS), a proxy advisory firm, recommended that shareholders approve Kimberly-Clark’s $40 billi ...

Market Overview - The U.S. stock market experienced significant declines, with over 70.7% of U.S. issues falling on Tuesday, while only 26.4% advanced [2] - The Nasdaq Composite and S&P 500 dropped by 2.39% and 2.06% respectively, with the Dow and Russell 2000 also showing losses of 1.76% and 1.20% [3] Earnings Reports - Major earnings reports expected today include Johnson & Johnson, Charles Schwab, and Prologis, with a focus on regional banks reporting in both premarket and aftermarket sessions [5] - The S&P Regional Bank ETF ($KRE) is anticipated to be particularly responsive to these reports, having risen over 14% since its lows in November 2025 [6]

格隆汇1月21日｜强生(JNJ.US)：第四季度销售额为245.6亿美元，高于预期的241.5亿美元。预计2026财 年运营销售额为995亿至1005亿美元，高于预估的989亿美元。 ...

本文源自：金融界AI电报 强生(JNJ.N)预计2026财年运营销售额为995亿至1005亿美元，高于预估的989亿美元。 ...

Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with... ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The healthcare company's forecast for 2026 tops Wall Street's expectations. ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,†said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros. ...